BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Reuters2024-12-19
BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application <a href="https://laohu8.com/S/BLA.AU">$(BLA.AU)$</a> To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Dec 18 (Reuters) - Savara Inc SVRA.O:

  • SAVARA INITIATES ROLLING SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* FOR THE POTENTIAL TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

  • SAVARA INC - EXPECTS TO COMPLETE BLA SUBMISSION BY END OF 1Q 2025

  • SAVARA INC - TO REQUEST PRIORITY REVIEW OF BLA

Source text: ID:nBw7qmtCLa

Further company coverage: SVRA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment